![[Adobe Stock]](https://sp-ao.shortpixel.ai/client/to_webp,q_glossy,ret_img,w_750,h_375/https://www.psypost.org/wp-content/uploads/2025/06/neurons-750x375.jpg)
New research suggests that a single dose of the psychedelic compound DMT can reverse symptoms of depression, including loss of pleasure and cognitive decline, in mice subjected to chronic stress. The findings provide evidence that the drug helps repair brain circuitry by promoting the healthy growth and integration of new neurons. The study was published in the journal Translational Psychiatry.
Major depressive disorder is a leading cause of disability worldwide. Conventional antidepressants like selective serotonin reuptake inhibitors often take weeks to work and fail to help a significant portion of patients. This delay and lack of efficacy highlight a need for faster and more reliable therapeutic options.
In recent years, scientists have noticed that classical psychedelics can rapidly alleviate depressive symptoms. One such compound is N,N-dimethyltryptamine, commonly known as DMT, which naturally occurs in various plants and animals. It is also the primary active ingredient in ayahuasca, a traditional brewed tea used in Amazonian ceremonies.
When administered on its own, DMT produces an intense but very short-lived psychedelic experience that alters perception and mood. The drug works primarily by interacting with specific serotonin receptors in the brain, which are cellular structures that help regulate emotions.
However, clinical enthusiasm for psychedelics is moving faster than the biological understanding of how they work. Much of the past animal research on DMT has focused on basic anxiety responses rather than the more complex and stubborn symptoms of depression.
“A major gap in psychedelic research is that clinical translation is moving faster than our understanding of the underlying biology and of the conditions under which these compounds actually help,” said study author Thiago C. Moulin, a researcher at Uppsala University in Sweden.
“In the DMT literature, many animal studies focus on anxiety-like outcomes, while major depression is also marked by anhedonia and cognitive deficits, which are often harder to treat. We designed this study to test pure DMT in a well-established chronic-stress model and to ask whether behavioral recovery goes together with measurable repair in adult hippocampal neurogenesis and circuit integration.”
For their new research, the scientists used a sample of 48 male mice that were genetically modified to allow researchers to visually tag and track newborn neurons. The mice were subjected to a prolonged stress model for 56 days. This model involves exposing the animals to unpredictable, mild daily stressors, such as tilted cages or changes in lighting, to induce a depressive-like state.
The researchers divided the mice into several experimental groups to test different treatment timings and conditions. One group received a single injection of DMT at a dose of 30 milligrams per kilogram of body weight after the stress period ended. Another group received the same dose of DMT midway through the stress protocol on day 28.
A third group received DMT while under isoflurane anesthesia to test whether a conscious psychedelic experience was required for the drug to work. For comparison, another group of stressed mice received daily doses of fluoxetine, a standard antidepressant, for 30 days. The scientists also maintained a control group of non-stressed mice and a group of stressed mice that only received an inactive saline injection.
To measure anhedonia, the scientists tracked the animals’ preference for drinking sweetened water over regular water. Stressed mice typically lose interest in the sugar water, indicating a loss of pleasure. To assess cognitive function, the researchers used a complex radial arm maze task that tests working memory and the ability to distinguish between different spatial patterns.
The scientists found that the mice given DMT after the stress period fully recovered their preference for sugar water. These animals also showed improved cognitive performance in the maze task. A single dose of DMT actually outperformed the standard 30-day fluoxetine treatment across most of the behavioral tests.
The mice treated with DMT also showed a marked reduction in behavioral despair. Researchers measured this by tracking how long the mice remained immobile when temporarily suspended by their tails. When looking at the brain tissue, the researchers observed changes that aligned with these behavioral improvements.
The stressed mice that received saline had fewer new neurons in the dentate gyrus, a specific subregion of the hippocampus. Many of these new cells had also migrated to the wrong locations. This abnormal ectopic integration of cells disrupts healthy brain signaling and contributes to depressive symptoms.
DMT treatment increased the production of new neurons in the hippocampus. It also reduced the number of abnormally placed cells, restoring proper structure to the brain circuitry. The mice that received DMT under anesthesia still showed behavioral and cellular benefits, which suggests that the conscious psychedelic experience might not be strictly necessary to trigger brain repair.
The timing of the dose appeared to dictate the specific benefits. The mice that received DMT midway through the stress protocol showed protected mood behaviors, but they still suffered from cognitive deficits. This indicates that the drug reopens a window of brain plasticity, making the environment and timing central to complete functional recovery.
“In mice exposed to prolonged, unpredictable stress, a single dose of DMT improved depression-relevant behaviors, including loss of pleasure and stress-related cognitive impairment,” Moulin told PsyPost. “Importantly, these behavioral improvements aligned with brain-level changes: we saw not only effects on newborn neurons, but also a reduction in their abnormal integration, which is consistent with circuit-level repair. This is preclinical work, but it supports the idea that psychedelics may reopen plasticity in ways that can be beneficial when the timing is right.”
There are a few potential misinterpretations to avoid. This preclinical work does not prove that a single dose of DMT will instantly cure depression in humans. Mouse models capture specific elements of mood and cognition, but they cannot represent the full complexity of human psychiatric conditions.
“In this model, the effects were large relative to a standard SSRI control (fluoxetine), especially for anhedonia and the cognitive readout we used (pattern separation),” Moulin explained. “However, mouse effects often don’t translate directly into clinical impact in humans, where dose, context, and patient heterogeneity matter. I would frame it as: the signal is strong and consistent enough to justify deeper mechanistic work and careful clinical testing, not as a claim of immediate clinical equivalence.”
The anesthesia results also require conservative interpretation. While the anesthetized mice still experienced benefits, the drug’s effects were somewhat attenuated, which implies that the subjective psychedelic experience may still play a role in maximizing therapeutic outcomes. Isoflurane anesthesia can also have its own independent effects on the brain, making it difficult to completely isolate the impact of DMT.
The study only used male mice because the specific stress model is less consistent in female mice of this genetic background. Future research will need to include female subjects to determine if these biological responses differ by sex. Scientists also hope to map out the exact molecular pathways the drug activates and explore alternative delivery methods for human patients.
“We are working to connect the dots from receptor activation to circuit changes and behavior, and to map the ‘plasticity window,’ which is when intervention helps the most,” Moulin said. “We also want better translational readouts of psychedelic-like states in animals using non-invasive behavioral tracking. In parallel, we are exploring delivery strategies that are more clinically relevant than injections.”
“One point we think is important is that our findings suggest the benefits of the plasticity window depend on timing and context. In our model, DMT could prevent mood-related symptoms during ongoing stress, but the strongest cognitive rescue appeared when dosing occurred after the stress protocol ended. This reinforces the idea that increased plasticity creates an opportunity for change, but the surrounding conditions may shape whether that change translates into functional recovery.”
The study, “Single-dose DMT reverses anhedonia and cognitive deficits via restoration of neurogenesis in a stress-induced depression model,” was authored by Rafael V. Lima da Cruz, Rêmullo B. G. de Miranda Costa, Gabriel M. de Queiroz, Tijana Stojanovic, Thiago C. Moulin & Richardson N. Leão.
